We believe that TLR4-IN-C34 is a novel therapeutic strategy that decreases ISO-related AKI by modulating TLR4/NF-κB/MAPK/MYD88 signaling thereby attenuating inflammation, oxidative stress, and apoptosis. Here, NFKB1 is linked to acute kidney injury.